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Abstract
Background: Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with
chemotherapy is an effective treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).
However, only a small percentage of mCRC patients receive clinical benefits from anti-EGFR therapies, due to the
development of resistance mechanisms. In this regard, HER2 has emerged as an actionable target in the treatment
of mCRC patients with resistance to anti-EGFR therapy.
Methods: We have used SW48 and LIM1215 human colon cancer cell lines, quadruple wild-type for KRAS, NRAS,
BRAF and PI3KCA genes, and their HER2–amplified (LIM1215-HER2 and SW48-HER2) derived cells to perform in vitro
and in vivo studies in order to identify novel therapeutic strategies in HER2 gene amplified human colorectal
cancer.
Results: LIM1215-HER2 and SW48-HER2 cells showed over-expression and activation of the HER family receptors
and concomitant intracellular downstream signaling including the pro-survival PI3KCA/AKT and the mitogenic RAS/
RAF/MEK/MAPK pathways. HER2-amplified cells were treated with several agents including anti-EGFR antibodies
(cetuximab, SYM004 and MM151); anti-HER2 (trastuzumab, pertuzumab and lapatinib) inhibitors; anti-HER3
(duligotuzumab) inhibitors; and MEK and PI3KCA inhibitors, such as refametinib and pictilisib, as single agents and
in combination. Subsequently, different in vivo experiments have been performed. MEK plus PI3KCA inhibitors
treatment determined the best antitumor activity. These results were validated in vivo in HER2-amplified patient
derived tumor xenografts from three metastatic colorectal cancer patients.
Conclusions: These results suggest that combined therapy with MEK and PI3KCA inhibitors could represent a novel
and effective treatment option for HER2-amplified colorectal cancer.
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Background
In the last decade, the development of targeted anti-cancer
therapies has revolutionized the treatment of metastatic
colorectal cancer (mCRC) patients. In particular, monoclonal
antibodies (mAbs) targeting the epidermal growth factor re-
ceptor (EGFR) like cetuximab and panitumumab were the
first targeted agents to enter the clinical setting improving
the survival of mCRC patients [1, 2]. However, efficacy in
anunselected patient population was limited, whereas the
identification of biomarkers has led to significantly improved
patient selection [3]. In particular, mutations in KRAS and
NRAS genes are found to predict resistance to anti-EGFR
targeted therapies and are used in clinical practice to guide
treatment decision [4]. Furthermore, at least one third of
mCRC patients with RAS wild type tumors receiving
first-line chemotherapy in combination with anti-EGFR
mAbs fail to have a therapeutic response. These results indi-
cate that additional genetic alterations in genes implicated in
the EGFR signaling network can be involved in the primary
resistance [5–8]. In fact, deregulation of other effectors of
the EGFR signaling cascade, such as mutations in BRAF or
PIK3CA genes, loss of PTEN expression, and amplification
of KRAS may affect primary response to EGFR blockade [9–
12]. Despite the implementation of biomarkers in clinical
practice, patients who initially respond to anti-EGFR therap-
ies almost invariably develop secondary resistance through
several mechanisms. The most common molecular mecha-
nisms that are responsible for acquired resistance are genetic
alterations of KRAS, NRAS and BRAF genes [6, 13]. In the
absence of alteration in RAS or its immediate downstream
effectors, other mechanisms have been involved in the acti-
vation of the EGFR pathway. Genetic aberrations in receptor
tyrosine kinase (RTK), such as HER2 and MET, have been
shown to bypass EGFR signaling and activate the MAPK
cascade and, therefore, to confer acquired resistance to
anti-EGFR therapies [14–16]. In particular, HER2 amplifica-
tion has been suggested as both an intrinsic as well as an ac-
quired mechanism of resistance [17]. One explanation could
be that pre-exiting infrequent HER2-amplificated clones might
be expanded under the selective pressure of anti-EGFR ther-
apy, leading to disease progression. In this regard, HER2 amp-
lification was found in 5% of mCRC patients with RAS wild
type tumors and seem to be associated with resistance to anti-
EGFR therapy [18, 19]. In a large cohort of 85 patient-derived
colorectal cancer xenografts, Bertotti and colleagues identified
HER2 gene amplification in some xenografts, which were re-
sistant to cetuximab and did not harbour mutations in KRAS,
NRAS or BRAF genes [17, 20, 21]. Moreover, patient-derived
mCRC xenografts with HER2 amplification were treated with
various HER2-targeted therapies, alone or in combination. In
these preclinical models of human colorectal cancer, the com-
bination of an anti-HER2 antibody (pertuzumab or trastuzu-
mab) and an HER2 tyrosine kinase inhibitor (TKI) (lapatinib)
induced pronounced tumor shrinkage [17]. These preclinical
results were the proof of concept for clinical trials targeting
HER2 genetic alterations in mCRC patients [22]. The phase II
HERACLES-A trial of dual HER2-targeted therapy (trastuzu-
mab plus lapatinib) in patients with KRAS wild-type, HER2--
positive mCRC who were refractory to standard-of-care
treatments, including cetuximab or panitumumab was con-
ducted [23]. Of the 27 patients evaluated for efficacy, eight pa-
tients (30%) achieved an overall objective response, meeting
the primary endpoint of the trial. None of the patients en-
rolled who were evaluable for response to anti-EGFR therapy
had achieved an objective response with either cetuximab or
panitumumab. Based on these results, several clinical trials
have been conducted exploiting HER2 as a target for
mCRC and also case reports of patients with HER2-posi-
tive mCRC who have achieved substantial clinical benefit
with targeted anti-HER2 therapy have recently been pub-
lished [19, 24, 25]. However, 40–50% of patients treated
within the HERACLES-A trial did not achieve partial re-
sponse or prolonged stable disease despite HER2 gene
amplification [23, 26]. Notably, even in patients initially
responding, acquired resistance occurred in almost all
cases [23]. Understanding the mechanisms of resistance to
HER2 blockade is a priority to develop more effective and
additional options for therapy in this disease setting.
In order to elucidate the possible mechanism(s) of re-
sistance to anti-HER2 treatments, in this study we have
used LIM1215 and SW48 human colon cancer cell lines
and their HER2-amplified derivatives (LIM1215-HER2
and SW48-HER2) to perform in vitro and in vivo studies
using different xenograft models in order to identify
novel therapeutic options [17, 23, 26]. Furthermore, hu-
man mCRC patient derived tumor xenografts with HER2
gene amplification were used to further validate the po-
tential efficacy of these therapeutic strategies.
Methods
Drugs
5-Fluorouracil, oxaliplatin and irinotecan were obtained
from the pharmacy of the University of Campania “Luigi
Vanvitelli”. Cetuximab, panitumumab, SYM004, MM151,
trastuzumab, pertuzumab and duligotuzumab antibodies
were kindly provided by Merck, Amgen, Symphogen,
Merrimack Pharmaceuticals, Roche and Genentech, re-
spectively. Refametinib, a selective MEK 1/2 inhibitor was
kindly provided by Bayer Italy; Pictilisib, a PI3Kα inhibitor
and lapatinib were purchased from Selleckchem.
Human cancer cell lines
The human LIM1215 and SW48 colon cancer cell lines
were purchased from the American Type Culture Col-
lection (ATCC). Cells were grown in RPMI 1460
medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin and maintained in a humidi-
fied controlled atmosphere at 37 °C.
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Colony formation assay
LIM1215-HER2 and SW48-HER2 cells were treated with
different concentrations of trastuzumab, pertuzumab,
lapatinib, cetuximab, SYM004, MM-151, duligotuzumab,
refametinib and pictilisib alone and in combination (range:
0,05–10 μg/ml-μM), for 96 h. After 14 days, cells were
fixed with 4% paraformaldehyde and stained with crystal
violet. Finally, the plates were inspected by microscopy,
photographed and the colonies area was calculated by
ImageJ plugins [27]. Results represent the median of three
separate experiments, each performed in triplicate.
Western blot analysis
LIM1215-HER2 and SW48-HER2 cells were treated with
refametinib and pictilisib alone and in combination for 24 h.
Equal amounts of total proteins were incubated with follow-
ing primary polyclonal antibodies: EGFR and phospho-
EGFR, HER2 and phospho-HER2, HER3 and phospho-
HER3, HER4 and phospho-HER4, AKT and phospho-AKT,
MEK1/2 and phospho-MEK1/2, p44/42MAPK and
phospho-p44/42 purchased from Cell Signaling. Monoclonal
anti- α-tubulin antibody was provided by Sigma-Aldrich.
After incubation with secondary anti-goat antibody, the
membranes were developed using an enhanced chemi-lumi-
nescence (ECL) detection system (BioRad). As concerning
the in vivo experiments, tumor samples were homogenized
as previously described [28]. Indicated proteins were probed
with the same antibodies, as described above.
Tumor xenografts in nude mice
Four- to six-week old female balb/c athymic (nu+/nu+)
mice were purchased from Envigo Laboratories. Three
different in vivo experiments were performed. Briefly for
the first experiment, mice were injected subcutaneously
in the right flank with LIM1215-HER2 and SW48-HER2
cells and were randomly assigned to one of the following
groups (10 mice/group). Group 1: vehicle administrated
intraperitoneally (i.p.); group 2: refametinib adminis-
trated by oral gavage (o.g.) every day (25 mg/kg); group
3: pictilisib administrated by o.g. every day (75 mg/kg);
group 4: combined treatment of refametinib (25 mg/kg)
and pictilisib (75 mg/kg). Treatments were continued for
4 weeks. In the second in vivo experiment, groups of 90
mice injected in the right flank with LIM1215-HER2 and
SW48-HER2 cells were treated with oxaliplatin (10 mg/
kg) once every 2 weeks (i.p) plus trastuzumab (10 mg/
kg) twice a week (i.p). At the end of 4 weeks treatment
(induction treatment), mice were randomized into one
of the following nine groups: Group 1: Veichle control;
group 2: Pictilisib administrated by o.g. every day (75
mg/kg); group 3: refametinib administrated by o.g. every
day (25 mg/kg); group 4: trastuzumab (10 mg/kg) twice a
week i.p.; group 5: refametinib plus trastuzumab; group
6: pictilisib plus trastuzumab; group 7: pictilisib plus
refametinib; group 8: lapatinib plus trastuzumab;
group 9: the triplet combination of pictilisib, refameti-
nib and trastuzumab. All drugs in the combined
treatment are used at same concentration as single
agent. Treatments continue for 8 weeks (maintenance
treatment) and afterwards animals were followed for
additional 16 weeks (follow-up period). At the end of
maintenance treatment, one animal per group was
sacrificed and tumor sample were collected for west-
ern blot analysis. In the third in vivo experiment,
mice injected in the right flank with LIM1215-HER2
and SW48-HER2 cells were divided into four groups.
Group 1: Vehicle control; group 2: refametinib (25
mg/kg) plus pictilisib (75 mg/kg) for 26 weeks; group
3: lapatinib (30 mg/kg) plus trastuzumab (10 mg/kg)
for 26 weeks; group 4: lapatinib (30 mg/kg) plus tras-
tuzumab (10 mg/kg) until progression. At the time of
progression to lapatinib plus trastuzumab, mice were
treated in second-line with combination of refameti-
nib (25 mg/kg) and pictilisib (75 mg/kg). Tumor vol-
ume was measured using the formula π/6 × larger
diameter x (smaller diameter)2. For monitoring tumor
responses to therapy, we measured volumetric
changes and used an arbitrary classification method
modified from clinical research methods as previously
reported [28].
Tumor specimen collection and annotation
Tumor and matched normal samples were obtained from
patients treated by liver metastasectomy at the Candiolo
Cancer Institute (Torino, Italy), Mauriziano Umberto I,
and San Giovanni Battista (Torino). All patients provided
informed consent.
Patient derived xenograft (PDX) models and in vivo
treatments
Tumor implantation and expansion were performed in
6-week-old NOD/SCID mice as previously described [17,
29]. Mice were randomized and treated with the following
agents: trastuzumab; refametinib; pictilisib. Tumor size
was measured twice a week. Results were considered in-
terpretable when a minimum of 4 mice per treatment
group reached the pre-specified endpoints (at least 3
weeks on therapy or development of tumors with volumes
larger than 1500mm3) [30].
Statistical analysis
Statistical analyses of the in vitro data were performed
using a one-way analysis of variance (ANOVA). Quanti-
tative data were reported as mean ± standard deviation
(SD). Results were compared by ANOVA.
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Results
In vitro generation and characterization of HER2-
amplified human colorectal cancer cell lines
The human CRC cell lines SW48 and LIM1215 harbor the
wild type (WT) KRAS, NRAS, BRAF, and PIK3CA genes
and are considerate an optimal preclinical model of EGFR
therapeutic blockade. Since both cell lines have no or little
expression of HER2 protein, they were transfected with
HER2 gene in order to generate their HER2-amplified de-
rivatives cells (SW48-HER2 and LIM1215-HER2). Trans-
fection of HER2 gene results in cell stably overexpressing
the HER2 protein (Additional file 1: Figure S1).To
characterize the phenotype of these cells, we have studied
the HER2 protein function on cell mobility. As illustrated
in Additional file 1: Figure S2 A-B, parental SW48 and
LIM1215 cells exhibited significant migratory capability.
On the contrary their HER2-amplified derivatives cells
demonstrated no ability in migration. These findings sug-
gest that the amplification of HER2 gene is responsible of
epithelial-mesenchymal-transition (EMT) loss. To further
support this hypothesis, the expressions of epithelial- and
mesenchymal-related proteins were measured. As depicted
in Additional file 1: Figure S2 C-D, protein expression of
different epithelial and mesenchymal markers changes be-
tween parental and HER2-amplified derivatives cells. In par-
ticular, the expressions of vimentin and slug, two
mesenchymal markers, were decreased or suppressed in
SW48-HER2 and LIM1215-HER2 cells, as compared to
parental cells, respectively. On the contrary, E-cadherin, a
common epithelial marker, strongly increased in both
HER2-amplified derivatives cells as compared to parental
cells. Collectively, these results suggest that colon cancer
cell lines with HER2 amplification have lost an invasive be-
havior and have acquired an epithelial phenotype. In this
scenario, we have performed additional western blot ana-
lyses to evaluate differential expression of other HER family
receptors and their downstream effectors among parental
cell lines SW48 and LIM1215 and their derived, HER2-am-
plified cancer cells. Western blot analysis showed an in-
creased expression and phosphorylation of EGFR, HER3
and HER4 in HER2-amplified derivatives, that could lead to
a complex intracellular signaling which includes the activa-
tion of the pro-survival PI3KCA/AKT pathway and of the
mitogenic MAPK pathway [31, 32]. Activation of MAPK,
MEK and AKT with an increase in their phosphorylated
forms was observed in both HER2-amplified cells as com-
pared to their parental counterpart (Additional file 1: Figure
S3 A-B and Additional file 2: Table S1).
It has been demonstrated that HER2 is the only mem-
ber of the HER family receptors that has no ligand and,
therefore, it is activated mostly via hetero-dimerization
with other HER family receptors [24, 33]. Therefore, we
have analyzed whether the activation of AKT and MAPK ef-
fectors in HER2-amplified colon cancer cells could be due to
the interaction of HER2 with other HER family receptors.
For this purpose, SW48, SW48-HER2, LIM1215, LIM1215-
HER2 protein extracts were immune-precipitated with a spe-
cific anti-HER2 antibody and then assayed by western blot-
ting with a specific anti-HER3, anti-HER4 and anti-EGFR
antibodies. As shown in Additional file 1: Figure S3-C, HER2
immuno-precipitated together with HER3 and EGFR form-
ing HER2/HER3 and HER2/EGFR complexes only in
SW48-HER2 and LIM1215-HER2 cells, but not in SW48
and LIM1215 cells. No immune-complexs were formed be-
tween HER2 and HER4 (data not shown). These data sug-
gested the activation of HER2 signaling and this effect leads
to activation of the pro-survival PI3K/AKT pathway and the
mitogenic MAPK pathway through HER2/HER3 and HER2/
EGFR heterodimerization.
Sensitivity to chemotherapeutic agents and to anti-EGFR
monoclonal antibodiesin parental and in HER2-amplified
human colon cancer cell lines
We first tested in vitro the activity of different chemo-
therapeutic agents in both parental and HER2–ampli-
fied colon cancer cell lines. All cancer cells we treated
with 5-fluorouracil, oxaliplatin and irinotecan for 96 h.
As shown in Additional file 1: Figure S4-A, there was no dif-
ferential sensitivity to chemotherapies among all cancer cells.
We next evaluated the sensitivity to the cell growth inhibit-
ing effects of different anti-EGFR mAbs, including cetuxi-
mab, panitumumab, SYM004, and MM-151. As shown in
Additional file 1: Figure S4-B, there was a differential sensi-
tivity to anti-EGFR mAbs-induced cell growth inhibition. In
fact, parental SW48 and LIM1215 cancer cells were signifi-
cantly sensitive to cetuximab, panitumumab, SYM004 and
MM-151 antibodies inducing growth inhibition, as expected
being “quadruple wild type” for KRAS, BRAF, NRAS and
PIK3CA genes. On the contrary, HER2-amplified colon can-
cer cells were resistant to all anti-EGFR inhibitors, expanding
and confirming the results from previous studies regarding
the role of HER2 amplification in either primary and ac-
quired resistance to EGFR targeted therapies [17, 34, 35].
Effects of anti-HER2 inhibitors alone and/or in
combination with anti-EGFR and anti-HER3 monoclonal
antibodies on HER2-amplified human colon cancer cells
In previous studies, it has been demonstrated that HER2
amplification represents not only a biomarker of resist-
ance to EGFR inhibition, but also a positive predictor of
response to HER2 targeting agents [17]. In fact, mCRC
patient derived xenografts with HER2 amplification were
sensitive to HER2-blockade with trastuzumab in combin-
ation with lapatinib, but not to either agent alone. In
HER2-amplified colon cancer cells monotherapy with either
HER2 tyrosine kinase inhibitor or anti-HER2 antibodies was
almost ineffective, whereas only the combination of a mono-
clonal antibody, trastuzumab, and a tyrosine kinase inhibitor,
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lapatinib, induced a significant anti-proliferative activity
(Fig. 1a-e). Our data showed that, whereas pertuzumab, tras-
tuzumab and lapatinib treatments had no or little effects as
single agents on cell growth in LIM1215-HER2 and
SW48-HER2 cells, a dual blockade of HER2 with trastuzu-
mab and lapatinib had the most anti-proliferative effect com-
pared to other treatments (Fig. 1 a-e). Moreover, this effect
was not ameliorated by the addition of the other two
anti-HER2 mAbs, as trastuzumab and pertuzumab. Further-
more, in HER2-amplified LIM1215-HER2 and SW48-HER2
colon cancer cells HER2 activation was accompanied by the
interaction of HER2 with both EGFR and HER3, respectively,
by forming HER2/EGFR and HER2/HER3 complexes.
Therefore, we investigated whether a dual blockade of HER2
by using lapatinib and trastuzumab, that is considered the
most active therapeutic strategy, in combination with
anti-EGFR or anti-HER3 inhibitors could be a more effective
treatment in HER2-amplified cells. As depicted in Fig. 1 a-e,
the addiction of anti-EGFR mAbs to lapatinib plus trastuzu-
mab combined treatment antagonized the anti-proliferative
activity of the dual anti-HER2 blocked. In particular, in
LIM1215-HER2 cells the IC50 for the triplet combination
with trastuzumab, lapatinib and cetuximab was 3 μg/ml, 60
times higher than the IC50 of dual anti-HER2 blockade. Simi-
lar results were obtained by using triplet combinations with
the anti-HER3 antibody duligotuzumab (Fig. 1 a-e).
Effects of refametinib and pictilisib on cell proliferation
and on EGFR-dependent intracellular pathways in
parental SW48 and LIM1215 and in HER2-amplifiedhuman
colon cancer cell lines
Given the observed concomitant activation of MAPK and
PI3KCA-driven intracellular signals in HER2-amplified colon
cancer cells, we next evaluated the cell growth inhibiting ef-
fects of a selective MEK1/2 inhibitor, refametinib, and of a
selective PI3Kα inhibitor, pictilisib, as single agents or in
combination. First, to evaluate the sensitivity to MEK and/or
PI3KCA inhibitors between parental and derived cells,
SW48, LIM1215, SW48-HER2 and LIM1215-HER2 cell
lines were treated with both drugs as a single agent. As
shown in Fig. 2-a, although refametinib and pictilisib treat-
ments caused a dose-dependent cell growth inhibition in all
colon cancer cell lines, the HER2-amplified cells were more
sensitive to both drugs, as single agents, compared to paren-
tal cells at all concentrations tested. Next, we evaluated
whether the treatment of refametinib in combination with
pictilisib could induce a more effective anti-proliferative
effect as compared to single treatments in HER2-am-
plifed colon cancer cell lines. The combined treatment with
refametinib and pictilisib induced significant growth inhib-
ition in both SW48-HER2 and LIM1215-HER2 cells (Fig.
2-b). To further evaluate if anti-HER2 blockade with trastu-
zumab or lapatinib could increase the anti-proliferative ef-
fects of refametinib plus pictilisib, SW48-HER2 and
LIM1215-HER2 cells were treated with trastuzumab, lapati-
nib, refametinib and pictilisib, in different combinations. As
depicted in Fig. 2-b, treatments with anti-HER2 agents, tras-
tuzumab and lapatinib alone and in combination, had no ef-
fect when added to the refametinib plus pictilisib combined
treatment. These results suggest that combination of refame-
tinib plus pictilisib is more effective than lapatinib plus tras-
tuzumab combined treatment and that the addition of
anti-HER2 drugs to MEK and PI3KCA inhibitors does
not significantly increase cell growth inhibition in these
HER2-amplified colon cancer models. To better understand
whether the anti-tumor activity obtained by the combined
treatment with MEK and PI3KCA inhibitor was due to a
more effective inhibition of key intracellular signals, EGFR
downstream signaling pathways were evaluated. SW48-HER2
and LIM1215-HER2 cells were treated with refametinib, pic-
tilisib and/or their combination. The combined treatment
with refametinib plus pictilisib substantially inhibited the ex-
pression of EGFR, HER2, HER4 and their downstream effec-
tors, such as AKT, MEK, and MAPK in their total forms and
consequently the combination blocked their activation com-
pared with single-agent treatments after 24 h of incubation.
The concomitant block of PI3KCA/AKT and MAPK path-
ways could generate a negative feedback loop that led to the
reduction in expression and activation of proteins. However,
further investigation is needed to elucidate in detail these
molecular mechanisms (Fig. 2c).
Effects of refametinib and pictilisib on HER2-amplified
human cancer xenografts
Subsequently, we investigated the in vivo antitumor ac-
tivity of refametinib and pictilisib. Mice injected with
LIM1215-HER2 and SW48-HER2 cells were randomly
assigned to receive vehicle, refametinib (25 mg/kg), picti-
lisib (75 mg/Kg) or their combination for 4 weeks. As
shown in Fig. 3, treatment with refametinib had little or
no effect on tumor growth in both tumor xenografts.
Similar results were obtained in the groups treated with
pictilisib alone. On the contrary, the combined treat-
ment suppressed almost completely LIM1215-HER2 and
SW48-HER2 tumor growth at the end of the 4 weeks of
therapy (Fig. 3 a-b). This complete suppression of tumor
growth in the combined treatment group was long last-
ing up to week 20.
Antitumor efficacy of oxaliplatin plus trastuzumab
followed by maintenance treatment with different
inhibitors alone or in combination with trastuzumab in
HER2-amplified human cancer xenografts
In a subsequent in vivo experiment, two groups of 90
nude mice were injected subcutaneously with each HER2--
amplified cancer cells and were treated for 4 weeks with
the combination of oxaliplatin plus trastuzumab. At the
end of this treatment, mice were randomized into nine
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groups and treated for 8 weeks with different inhibitors,
including refametinib, pictilisib, lapatinib and trastuzumab
alone or in combination (maintenance period) (Fig. 4) a-c.
After the maintenance period, mice were followed for an
additional 16 weeks. At the end of the maintenance treat-
ment (week 14), among the single-agent treatments, the
group treated with trastuzumab showed the greatest
tumor growth inhibition in both xenograft models with a
mean tumor volume of 971 and 1500mm3, respectively
(Fig. 4 a-c and Additional file 2: Table S2). In fact, the
growth rate of tumors treated with pictilisib and refameti-
nib as single agent was similar to those treated with ve-
hicle regardless of cell lines injected reaching the
maximum allowed tumor size of 2000mm3 (Fig. 4 a-c and
Additional file 2: Table S2). In the combined treatment
groups, although the addition to refametinib and/or picti-
lisib to trastuzumab caused a strong antitumor activity in
both xenograft models, the most effective antitumor
Fig. 1 Effects of dual block of anti-HER2 inhibitors alone and/or in combination with anti-EGFR and anti-HER3 mAbs on HER2-amplified (SW48-
HER2 and LIM1215-HER2) human colon cancer cells. a-e Cells sensitivity to different drugs was evaluated by clonogenic assay in LIM1215-HER2
and SW48-HER2 cells. Data were represented as cell colony area calculated by ImageJ software after staining with crystal violet, as described in
Materials and Methods. e Table with IC50 value for each drug, used as single agent or in combination
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activity was observed with the combined treatment of
refametinib plus pictilisib. In particular, this combination
caused an almost complete suppression of tumor growth
in LIM1215-HER2 and SW48-HER2 tumor xenografts
with a mean tumor volume of 75 and 103mm3, respect-
ively. Moreover, only in this treatment group mice with no
evidence of tumors were observed (Fig. 4 a-c and Add-
itional file 2: Table S2). Mice were followed for additional
16 weeks (follow-up period) from the end of the treatment
to evaluate which maintenance strategy could determine a
more sustained and prolonged tumor growth control. In
the combined trastuzumab plus refametinib or pictilisib
groups, tumors started to regrowth immediately after the
cessation of treatment. Indeed, 3 to 5 weeks after cessation
of treatment the tumor growth rate in these combined
treatment groups was comparable to the tumor growth
rate in the trastuzumab group for both HER2-amplified
cancer models. On the contrary, the anti-tumor activity of
Fig. 2 Effects of refametinib and pictilisib alone and in combination on colonies formation and on EGFR-dependent intracellular signaling in parental
SW48 and LIM1215 human colon cancer cell lines and in their HER2-amplified derivatives (SW48-HER2 and LIM1215-HER2). a Both parental and HER2-
amplified derivatives cells were treated with different concentrations of refametinib and pictilisib as single agents (range, 0.05 to 10 μM), for 96 h and
evaluated byclonogenic assay. Data were represented as cell colony area percentage calculated by ImageJ software after staining with crystal violet, as
described in Materials and Methods. b SW48-HER2 and LIM1215-HER2 cell lines were treated with lapatinib, trastuzumab, refametinib and pictilisib at
0.5 μM, as single agent and in their possible combinations (**p < 0.01 compared to other treatments). Colony area percentage was presented in the
Table. c SW48-HER2 and LIM1215-HER2 cells were treated with refametinib and pictilisib (0.5 μM) alone and in combination for 24 h. Cell protein
extracts were subjected to immunoblotting with the indicate antibodies, as described in Materials and Methods. α-Tubulin was used as the loading
control. Results represent the mean of three separate experiments, each performed in duplicate
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the combined refametinib plus pictilisib treatment was
still maintained within 13 to 16 weeks after the cessation
of therapy. In particular, in this combined treatment group
almost half of the mice were still alive at the end of the
follow-up period (Fig. 4a-c and Additional file 2: Table
S2). Moreover, in order to evaluate the mechanism(s) by
which the combined treatment with refametinib plus pic-
tilisib was able to induce a significant and long lasting an-
titumor activity, one mouse for each group treated with
refametinib, pictilisib or with their combination was sacri-
ficed at the end of the maintenance treatment. As shown
in Fig. 4-d, the combined treatment with refametinib plus
pictilisib was the only treatment able to substantially in-
hibit the expression and activation of HER receptors fam-
ily and their downstream effectors in their total forms at
the end of the maintenance treatment.
To further dissect the effects of refametinib plus pictilisib
combined treatment on HER2-amplified xenograft models,
LIM1215-HER2 and SW48-HER2 cells were injected sub-
cutaneously into nude mice and were treated with veichle,
lapatinib plus trastuzumab or pictilisib plus refametinib
until tumors increased growth (Fig. 5 a-b). When tumors
were growing despite treatment with lapatinib plus trastu-
zumab, treatment with refametinib plus pictilisib was
started. As shown in Fig. 5, treatment with refametinib plus
pictilisib provided further antitumor activity. However, this
effect was transient. In fact, after 5 weeks of this therapy, tu-
mors started to regrowth reaching the maximum allowed
tumor size of 2000mm3 at week 26. On the contrary, the
group of mice treated with refametinib plus pictilisib from
the beginning of the experiment experienced the best anti-
tumor efficacy with no evidence of tumor progression up
Fig. 3 Effects of refametinib and pictilisib on LIM1215-HER2 and SW48-HER2 tumor xenografts. Mice were injected subcutaneously in the right
flank with (a) LIM1215-HER2 and (b) SW48-HER2 cell lines, as described in Materials and Methods. After 2 weeks (average tumor size 200 mm3)
mice were treated with refametinib (25 mg/kg every day, by o.g.) and pictilisib (75 mg/Kg every day, by o.g.), as single agents and in combination,
for 4 weeks. Thereafter, tumor growth was followed without any further treatment until the 20th week. Data are means ± SD of ten mice in
each group
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to week 26 (Fig. 5 a-b). Moreover, the combined treatment
with refametinib plus pictilisib as initial therapy substan-
tially inhibited phosphorylation of EGFR, HER2, HER3,
HER4 and of downstream signaling pathways such as
MEK, MAPK, and AKT, as measured by western blotting
at the end of the treatment period (Fig. 5-c). Collectively,
these data support the hypothesis that in HER2-amplified
colon cancer xenografts treatment with refametinib plus
pictilisib is more effective as initial therapy in order to
better control the onset of cancer cell resistance mecha-
nisms, that are more frequent and develop earlier with
HER2 blockade.
Effect of refametinib and pictilisib combined treatment
with or without trastuzumab in HER2-amplified metastatic
colorectal cancer patient derived tumor xenografts
One way to proceed with efficient, high-fidelity drug
development at the stage of in vivo validation while
Fig. 4 Effect of maintenance treatment with different kinase inhibitors alone or in combination with trastuzumab, after induction therapy with
oxaliplatin plus trastuzumab in HER2-amplified colon cancer xenograft models. HER2-amplified colon cancer cells (SW48-HER2 and LIM1215-HER2)
were injected into the right flank of nude mice. After 2 weeks of subcutaneous injection, mice were treated with oxaliplatin (10 mg/kg once
every 2 weeks, i.p.) in combination with trastuzumab (10 mg/kg twice a week, i.p.) for 4 weeks (induction treatment). Afterward, mice were
randomized into nine groups and treated for 8 weeks (maintenance treatment). Ctrl: control; pictilisib (75 mg/Kg) and refametinib (25 mg/kg)
were administrated every day for 5 days by o.g, as single agents and in different combinations; trastuzumab (10 mg/kg twice a week, by i.p.) and
lapatinib (30 mg/kg every day, by o.g.) as single agents and in different combinations. a Treatment scheme. Red boxes: pictilisib treatment days;
green boxes: refametinib treatment days; violet boxes: trastuzumab treatment days; light blue boxes: lapatinib treatment days. b–c Antitumor
activity of maintenance treatment in SW48-HER2 and LIM1215-HER2 tumor-bearing mice. The indicated cancer cell lines were grown as
subcutaneous tumor xenografts in nude mice and treated with different drugs as indicated above. The mean data are present. Tumor growth
curves were calculated on the basis of three times a week tumor measurements during the treatment period and after 16 weeks of observation
after termination of therapy. d Analysis of EGFR-dependent intracellular signaling by western blotting in LIM1215-HER2 colorectal cancer
xenograft. At the end of maintenance treatment, 1 mouse per group treated with refamentinib, pictilisib or with their combination was sacrificed.
Tumor samples were collected, and total cell protein extracts were subjected to immunoblotting with the indicated antibodies, as described in
materials and methods. Anti-tubulin antibody was used for normalization of protein extract content
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minimizing the effects of uncharacterized tumor het-
erogeneity is to perform preclinical population-based
studies by using human cancer specimens directly
transplanted into mice (“xenopatients”) [17]. For this
reason, to further evaluate the antitumor efficacy of
refametinib plus pictilisib as a therapeutic strategy for
HER2-amplified colon cancer we used patients derived
tumor xenografts (PDTXs), by selecting three repre-
sentative cases (CRC 1432, CRC 1430 and CRC 0186)
of HER2-amplified tumors from mCRC patients [17].
For each experiment, mice were divided into four
groups and treated for 5 weeks with vehicle, trastuzu-
mab, refametinib plus pictilisib or the triple combin-
ation of refametinib, pictilisib and trastuzumab (Fig. 6
a-b). The combination treatment with refametinib
plus pictilisib and triple combination of refametinib,
pictilisib and trastuzumab were highly effective in
suppressing tumor growth, as compared to either the
vehicle-treated controls or the trastuzumab single
agent treatment group. Moreover, the combined treat-
ment with refametinib plus pictilisib exhibited an
even greater antitumor activity as compared to the
triple combination.
Discussion
In the past decade, the development of targeted therap-
ies has provided new options for the personalized man-
agement of patients with advanced solid tumors [1]. In
particular, CRC represents a heterogeneous group of dis-
eases with different sets of genetic events, accompanying
immune response, and influences of exogenous factors,
providing a challenge for personalized therapeutic ap-
proaches [1]. The mAbs directed against the EGFR, such
as cetuximab and panitumumab, are currently approved
for the treatment of patients with mCRC [1–5]. Despite
significant progress in strategies for cancer treatment,
these therapies have improved patient responses and
their use is limited by the presence of pre-existing
Fig. 5 Effect of refametinib and pictilisib combined treatment after tumor progression due to lapatinib plus trastuzumab therapy in HER2-
amplified colon cancer xenograft models. a-b SW48-HER2 and LIM1215-HER2 were injected into right flank of nude mice. After 2 weeks from
subcutaneous injection, mice were divided in four groups and treated for 26 weeks. Group 1: ctrl. Group 2: lapatinib (30 mg/kg every day, o.g.)
and trastuzumab (10 mg/kg twice a week, i.p.) were administrated in combination. Group 3: refametinib (25 mg/kg every day, o.g.) and pictilisib
(75 mg/Kg every day, o.g.) were administrated in combination. Group 4: mice were treated with combination of lapatinib (30 mg/kg every day,
o.g.) and trastuzumab (10 mg/kg twice a week, i.p.) until progression (defined as > 30% increment of tumor volume from baseline). After tumor
progression of group 4, mice were treated in second-line with combination of refametinib and pictilisib. c Tumor samples were collected and
total protein extracts were subjected to immunoblotting with all antibodies, as described in materials and methods section. Anti-tubulin antibody
was used for normalization of protein extract content
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intrinsic resistance mechanisms or by the ability of can-
cer cells to acquire resistance [6–10].
One of major mechanism of acquired resistance to
anti-EGFR mAbs is the activation of growth-factor sig-
naling pathways by upregulation of alternative and com-
pensatory signaling cascades through receptors other
than EGFR [14–16]. In particular, HER2 amplification
has been suggested as a mechanism of resistance [14,
17]. One explanation could be that pre-existing infre-
quent HER2-amplified clones might be expanded under
the selective pressure of anti-EGFR therapy, leading to
disease progression [20]. In this regard, HER2 amplifi-
cation is more likely to confer acquired anti-EGFR ther-
apy resistance. HER2 amplification was found in 5% of
mCRC patients harboring no mutation in KRAS, NRAS,
BRAF, PI3KCA genes [17–20] and together with “xeno-
patients” preclinical data provided the rational for
clinical studies with HER2-targeting therapies after fail-
ure of anti-EGFR treatments [17, 23, 24]. The
HERACLES-A clinical trial reported clinical meaningful
Fig. 6 Effect of refametinib and pictilisib combined treatment with or without trastuzumab in HER2-amplified metastatic colorectal cancer patient
derived tumor xenografts. Tumor samples with HER2 amplification derived from three different patients were directly implanted and expanded in
mice. a Representative tumor growth curves of tumors in xenopatients derived from quadruple-negative HER2-amplified cases CRC 1432,
CRC 130, CRC 0186 treated with the indicated modalities for 5 weeks: trastuzumab 10mg/kg i.p., twice weekly; refametinib 25mg/kg by o.g., daily;
pictilisib 75 mg/kg by o.g., daily. b Histogram represents the tumor volume of each treatment compared to the maximum growth of the control
at the fourth week
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responses to dual inhibitor HER2-directed therapy in a
subset of HER2-amplified mCRC patients, whose dis-
ease was refractory to chemotherapy and anti-EGFR
antibodies [23, 36].
Nevertheless, the mechanisms of resistance to HER2-
directed and EGFR-directed therapies are still unclear.
An improved understanding of the molecular character-
istics of HER2-amplified CRC models and their potential
mechanisms of resistance to HER2-directed therapy may
influence the direction of future research on targeted
therapies and inform future therapeutic decision-
making.With this aim, starting from quadruple wild-type
human CRC cells for KRAS, NRAS, BRAF and PI3KCA
genes (LIM1215 and SW48), we have generated HER2--
amplified (LIM1215-HER2 and SW48-HER2) cells. In
the current study, we report the up-regulation of HER
family receptors and over-expression of several markers
involved in RAS/RAF/MAPK and PI3KCA-AKT path-
ways in HER2-amplified cells compared to parental
colon cancer cells. Interestingly, these oncogenic path-
ways were activated by the interaction between HER2/
HER3 and HER2/EGFR, consequent to the heterodimer-
ization of these receptors. In agreement with these find-
ings, several studies have demonstrated that the
acquired resistance to anti-EGFR mAbs was associated
with the increased activation not only of HER2, but also
of HER3 and/or other alternative receptor tyrosine ki-
nases with consequent activation of EGFR-independent
intracellular downstream pathways [37, 38]. Based on
these data, in order to inhibit the compensatory feed-
back effect due to activation of downstream signaling
pathways, we have tested as therapeutic strategy the
combination of two selective MEK and PI3KCA inhibi-
tors, refametinib and pictilisib, respectively, in HER2-
amplified colon cancer cells (LIM1215-HER2 and
SW48-HER2). The combined treatment with refametinib
plus pictilisib determined a strong antitumor activity
both in vitro and in vivo, providing the rationale for the
further clinical development of this combination. In
particular, in nude mice bearing LIM1215-HER2 or
SW48-HER2 CRC tumor xenografts, the combined
treatment with refametinib plus pictilisib caused
complete tumor regression that lasted up to 20 weeks of
follow up after the end of treatment. These results sug-
gest that the concomitant blockade of two key intracel-
lular signaling hubs that could be involved in the
development of cancer cell resistance to anti-HER2 in-
hibitors might be a possible strategy to delay or prevent
its onset. Moreover, to extend the validation and the po-
tential clinical relevance of these findings, we have per-
formed an additional in vivo experiment. We treated
mice first with a combination of oxaliplatin plus trastu-
zumab for 4 weeks as a strategy to treat HER2-amplified
mCRC patients [23]. Before tumor started to regrowth
and eventually possible resistance mechanisms to tar-
geted agents would occur, mice were randomized to dif-
ferent maintenance treatments with several kinase
inhibitors, such as refametinib, pictilisib, lapatinib or
trastuzumab alone or in combination. The combined
treatment with refametinib plus pictilisib again was the
best therapeutic strategy also in this experimental main-
tenance therapy setting. Moreover, these findings have
been further validated in three HER2-amplified mCRC
patient derived xenografts, which could better resemble
the complexity of a human mCRC, since these models
have been demonstrated as a better surrogate of human
cancer and may represent a valid experimental tool to
overcome the limitations of in vitro models by faithfully
recapitulating the histological and functional heterogen-
eity observed in primary tumor samples. The combined
treatment with refametinib plus pictilisib exhibited a sig-
nificant antitumor activity, that was accompanied by a
sustained tumor growth inhibition in all three HER2-am-
plified mCRC patient derived xenografts.
Collectively, these data suggest that the dual and com-
bined inhibition of MEK and PI3KCA significantly inhibit
tumor growth in several different models of HER2-ampli-
fied CRC both in vitro and in vivo. In this respect, early
clinical trials have evaluated the combined inhibition of
MEK and PI3KCA signaling pathways in different tumor
types [39–42]. In particular, although the effect of PI3KCA
pathway activation as a mechanism of resistance to
HER2-directed therapy in CRC has not been directly in-
vestigated, activating mutations of PI3KCA and decreased
expression of PTEN have been identified as potential
mechanisms of resistance to trastuzumab and lapatinib in
breast cancer [43, 44]. A study using human breast cancer
cell lines and mouse tumor xenografts has shown that ac-
tivating mutations of PIK3CA and/or decreased expres-
sion of PTEN could be responsible of resistance to
lapatinib and that this resistance is reversible by double
blockade of PI3KCA and mTOR [45].
The ongoing Personalized Oncogenomics Group
(POG) trial (NCT02155621) has undertaken complete
molecular characterization of a total of 60 patients with
mCRC, two of which showed high-level of HER2 ampli-
fication. With the aim of better understanding mecha-
nisms of resistance to HER2-directed and EGFR-directed
therapies, Owen et al. reported the complete molecular
characterization of these two cases of HER2-amplified
mCRC. Their findings included increased expression of
MUC1 and MET, decreased expression of PTEN, and an
activating mutation in PIK3CA [46]. These data support
the hypothesis that a potentially promising alterative to
overcome resistance mechanisms would be to apply a
therapy in the upfront setting in order to suppress and
ideally eradicate pre-existing resistant clones while they
still are present in a low frequency subpopulation.
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Conclusions
In summary, the present study provides experimental evi-
dence that the combined treatment with refametinib plus
pictilisib could be a potential novel therapeutic strategy to
treat HER2-amplified mCRC patients with the aim of im-
proving the outcome of this aggressive disease subgroup
which is mostly refractory to standard therapies.
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